Introduction of the pneumococcal conjugate vaccine in humanitarian and fragile contexts: Perspectives from stakeholders in four African countries

被引:0
|
作者
Dhaliwal, Baldeep K. [1 ]
Weeks, Rose [1 ]
Huber, Jasmine [1 ]
Fofana, Aminata [1 ]
Bobe, Mohamed [2 ]
Mbailamen, Antoinette Demian [3 ]
Legge, George [4 ,5 ]
Cisse, Gassim [5 ]
Shet, Anita [1 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Dept Int Hlth, 415 N Washington St 535, Baltimore, MD 21231 USA
[2] Somalia Somaliland Country Off, Save Children, Mogadishu, Somalia
[3] Minist St Publ, Programme Elargi Vaccinat, Ndjamena, Chad
[4] Expanded Programme Immunisat EPI, Natl Minist Hlth, Juba, Sudan
[5] Expanded Programme Immunisat EPI, Minist Hlth & Publ Hyg, Conakry, Guinea
基金
比尔及梅琳达.盖茨基金会;
关键词
Pneumonia; pneumococcal conjugate vaccine; fragile contexts; health policy; decision-making;
D O I
10.1080/21645515.2024.2314828
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Childhood pneumonia causes a significant burden of preventable child morbidity and mortality in Chad, Guinea, Somalia/Somaliland, and South Sudan. Leaders from these countries have committed to reducing this burden and are preparing to introduce the pneumococcal conjugate vaccine (PCV) into their immunization programs. To support long-term sustainability for expected PCV introductions in settings afflicted by prolonged humanitarian crises this research explores national stakeholders' perspectives on contextual factors that may influence optimal vaccine implementation. This qualitative study used purposive sampling to identify and interview stakeholders involved in vaccine decision-making. Interview transcripts were analyzed through the framework method, an approach involving charting data into pre-populated matrices. Findings from interviews with 16 key informants from government, partner organizations, and international health agencies fit within the following four overarching themes: (1) population-level vulnerabilities to pneumonia, exacerbated by climatic risks and low levels of maternal education; (2) disease burden and the interest in enhancing surveillance to monitor vaccine impact and integrate disease control efforts; (3) policy processes, including formalizing vaccine decision-making; and (4) vaccine implementation preparation, including the conduct of robust communication campaigns, training, and cold chain upgrades. This research explores perspectives from leaders in these countries which are at pivotal moments in their journeys toward introducing PCV. Widespread commitment among leaders, in addition to financial support, will facilitate vaccine introduction. Further, fostering a shared understanding among partners about context-specific determinants of program success will help build tailored implementation strategies for each country.
引用
收藏
页数:9
相关论文
共 42 条
  • [1] Effectiveness of pneumococcal conjugate vaccine and rotavirus vaccine introduction into the South African public immunisation programme
    Madhi, S. A.
    Bamford, L.
    Ngcobo, N.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2014, 104 (03): : 228 - 234
  • [2] New pneumococcal conjugate vaccine introductions in four sub-Saharan African countries: a cross-country analysis of health systems' impacts
    Torres-Rueda, Sergio
    Burchett, Helen E. D.
    Griffiths, Ulla K.
    Ongolo-Zogo, Pierre
    Edengue, Jean-Marie
    Kitaw, Yayehyirad
    Molla, Mitike
    Gelmon, Lawrence
    Onyango-Ouma, Washington
    Konate, Mamadou
    Mounier-Jack, Sandra
    AFRICAN HEALTH SCIENCES, 2015, 15 (03) : 868 - 877
  • [3] Closing the pneumococcal conjugate vaccine (PCV) introduction gap: an archetype analysis of last-mile countries
    Banerjee, Preetika
    Huber, Jasmine
    Denti, Veronica
    Sauer, Molly
    Weeks, Rose
    Dhaliwal, Baldeep K.
    Shet, Anita
    GLOBAL HEALTH ACTION, 2023, 16 (01)
  • [4] Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries
    Talbird, Sandra E.
    Taylor, Thomas N.
    Knoll, Stefanie
    Frostad, Carl Richard
    Garcia Marti, Sebastian
    VACCINE, 2010, 28 : G23 - G29
  • [5] Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumococcal carriage in Fiji: results from four annual cross-sectional carriage surveys
    Dunne, Eileen M.
    Satzke, Catherine
    Ratu, Felisita T.
    Neal, Eleanor F. G.
    Boelsen, Laura K.
    Matanitobua, Silivia
    Pell, Casey L.
    Nation, Monica L.
    Ortika, Belinda D.
    Reyburn, Rita
    Jenkins, Kylie
    Nguyen, Cattram
    Gould, Katherine
    Hinds, Jason
    Tikoduadua, Lisi
    Kado, Joseph
    Rafai, Eric
    Kama, Mike
    Mulholland, E. Kim
    Russell, Fiona M.
    LANCET GLOBAL HEALTH, 2018, 6 (12): : E1375 - E1385
  • [6] Molecular Characterization of Invasive Meningococcal Isolates from Countries in the African Meningitis Belt before Introduction of a Serogroup A Conjugate Vaccine
    Caugant, Dominique A.
    Kristiansen, Paul A.
    Wang, Xin
    Mayer, Leonard W.
    Taha, Muhamed-Kheir
    Ouedraogo, Rasmata
    Kandolo, Denis
    Bougoudogo, Flabou
    Sow, Samba
    Bonte, Laurence
    PLOS ONE, 2012, 7 (09):
  • [7] Response to "Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries"
    Strutton, David
    Hwang, Sharon
    Farkouh, Raymond
    Roberts, Craig
    VACCINE, 2011, 29 (44) : 7589 - 7590
  • [8] HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine (PCV)
    Meiring, Susan
    Cohen, Cheryl
    Quan, Vanessa
    de Gouveia, Linda
    Feldman, Charles
    Karstaedt, Alan
    Klugman, Keith P.
    Madhi, Shabir A.
    Rabie, Helene
    Sriruttan, Charlotte
    von Gottberg, Anne
    PLOS ONE, 2016, 11 (02):
  • [9] NATIONAL PERSPECTIVES ON THE EUROPEAN JOINT CLINICAL ASSESSMENT: INSIGHTS FROM HTA STAKEHOLDERS IN FOUR COUNTRIES
    Mueller, E.
    Neeser, K.
    Koller, L.
    VALUE IN HEALTH, 2024, 27 (12) : S356 - S356
  • [10] Lessons learnt during the national introduction of human papillomavirus (HPV) vaccination programmes in 6 African countries: Stakeholders' perspectives
    Abdullahi, L. H.
    Hussey, G. D.
    Wiysonge, C. S.
    Kagina, B. M.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2020, 110 (06): : 525 - 531